Free Trial

Aldeyra Therapeutics (ALDX) Competitors

Aldeyra Therapeutics logo
$4.80 +0.28 (+6.19%)
Closing price 04:00 PM Eastern
Extended Trading
$4.85 +0.05 (+1.13%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ALDX vs. AVDL, ARDX, XERS, CRON, USNA, XNCR, KALV, RLAY, RGLS, and AMLX

Should you be buying Aldeyra Therapeutics stock or one of its competitors? The main competitors of Aldeyra Therapeutics include Avadel Pharmaceuticals (AVDL), Ardelyx (ARDX), Xeris Biopharma (XERS), Cronos Group (CRON), USANA Health Sciences (USNA), Xencor (XNCR), KalVista Pharmaceuticals (KALV), Relay Therapeutics (RLAY), Regulus Therapeutics (RGLS), and Amylyx Pharmaceuticals (AMLX). These companies are all part of the "med - drugs" industry.

Aldeyra Therapeutics vs. Its Competitors

Avadel Pharmaceuticals (NASDAQ:AVDL) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, media sentiment, valuation and dividends.

Avadel Pharmaceuticals has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500. Comparatively, Aldeyra Therapeutics has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500.

69.2% of Avadel Pharmaceuticals shares are owned by institutional investors. Comparatively, 59.7% of Aldeyra Therapeutics shares are owned by institutional investors. 5.2% of Avadel Pharmaceuticals shares are owned by insiders. Comparatively, 9.6% of Aldeyra Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Avadel Pharmaceuticals has higher revenue and earnings than Aldeyra Therapeutics. Avadel Pharmaceuticals is trading at a lower price-to-earnings ratio than Aldeyra Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avadel Pharmaceuticals$169.12M5.59-$48.83M-$0.27-36.19
Aldeyra TherapeuticsN/AN/A-$55.85M-$0.97-4.95

Aldeyra Therapeutics has a net margin of 0.00% compared to Avadel Pharmaceuticals' net margin of -13.58%. Avadel Pharmaceuticals' return on equity of -36.07% beat Aldeyra Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Avadel Pharmaceuticals-13.58% -36.07% -16.30%
Aldeyra Therapeutics N/A -72.58%-52.32%

Avadel Pharmaceuticals presently has a consensus target price of $18.17, indicating a potential upside of 85.94%. Aldeyra Therapeutics has a consensus target price of $9.50, indicating a potential upside of 97.92%. Given Aldeyra Therapeutics' higher probable upside, analysts plainly believe Aldeyra Therapeutics is more favorable than Avadel Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avadel Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00
Aldeyra Therapeutics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Avadel Pharmaceuticals had 5 more articles in the media than Aldeyra Therapeutics. MarketBeat recorded 7 mentions for Avadel Pharmaceuticals and 2 mentions for Aldeyra Therapeutics. Aldeyra Therapeutics' average media sentiment score of 0.75 beat Avadel Pharmaceuticals' score of 0.48 indicating that Aldeyra Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Avadel Pharmaceuticals
2 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Aldeyra Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Avadel Pharmaceuticals beats Aldeyra Therapeutics on 9 of the 14 factors compared between the two stocks.

Get Aldeyra Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALDX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ALDX vs. The Competition

MetricAldeyra TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$270.73M$2.43B$5.56B$9.04B
Dividend YieldN/A1.79%5.25%4.03%
P/E Ratio-4.959.3827.1820.14
Price / SalesN/A765.58440.78137.14
Price / CashN/A164.1737.5058.41
Price / Book4.034.698.085.60
Net Income-$55.85M$31.26M$3.16B$248.43M
7 Day Performance11.50%6.81%3.77%5.15%
1 Month Performance79.10%4.12%3.90%7.62%
1 Year Performance41.18%4.05%34.22%21.56%

Aldeyra Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ALDX
Aldeyra Therapeutics
2.6726 of 5 stars
$4.80
+6.2%
$9.50
+97.9%
+32.9%$270.73MN/A-4.9510
AVDL
Avadel Pharmaceuticals
2.7046 of 5 stars
$8.85
-3.8%
$18.17
+105.3%
-39.9%$890M$169.12M-32.7870
ARDX
Ardelyx
4.4608 of 5 stars
$3.92
+6.2%
$10.89
+177.8%
-17.3%$882.85M$333.61M-17.8290Analyst Revision
XERS
Xeris Biopharma
3.1101 of 5 stars
$4.67
-0.6%
$6.25
+33.8%
+147.2%$735.01M$203.07M0.00290News Coverage
CRON
Cronos Group
2.2936 of 5 stars
$1.91
+0.5%
N/A-7.1%$732.80M$117.61M0.00450News Coverage
USNA
USANA Health Sciences
3.4893 of 5 stars
$30.58
-1.8%
$36.00
+17.7%
-23.0%$579.74M$854.50M16.801,700Positive News
XNCR
Xencor
3.9991 of 5 stars
$7.86
-3.4%
$28.00
+256.2%
-49.3%$579.33M$110.49M-2.57280
KALV
KalVista Pharmaceuticals
4.1524 of 5 stars
$11.31
-0.9%
$24.83
+119.6%
+30.2%$567.26MN/A-3.04100Trending News
Earnings Report
Analyst Forecast
Analyst Revision
RLAY
Relay Therapeutics
2.5662 of 5 stars
$3.46
+4.8%
$17.67
+410.6%
-45.1%$565.77M$10.01M0.00330Positive News
Insider Trade
RGLS
Regulus Therapeutics
1.6373 of 5 stars
$8.16
flat
$8.50
+4.2%
N/A$564.92MN/A-11.1830
AMLX
Amylyx Pharmaceuticals
3.6762 of 5 stars
$6.41
+1.3%
$11.00
+71.6%
+338.8%$564.26M$87.37M0.00200News Coverage
Analyst Forecast

Related Companies and Tools


This page (NASDAQ:ALDX) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners